Marshall Wace
ATRA icon

Marshall Wace’s Atara Biotherapeutics ATRA Stock Holding History

Marshall Wace’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-148,632
Closed -$2.69M – 3182
2025
Q4 		$2.69M Buy
148,632
+32,836
+28% +$490K ﹤0.01% 1437
2025
Q3 		$1.66M Buy
115,796
+73,441
+173% +$845K ﹤0.01% 1709
2025
Q2 		$327K Buy
+42,355
New +$309K ﹤0.01% 2304
2025
Q1 		– Sell
-24,958
Closed -$332K – 2622
2024
Q4 		$332K Buy
+24,958
New +$263K ﹤0.01% 2201
2024
Q2 		– Sell
-1,690
Closed -$29.1K – 2530
2024
Q1 		$29.1K Sell
1,690
-10,010
-86% -$178K ﹤0.01% 2365
2023
Q4 		$149K Buy
+11,700
New +$273K ﹤0.01% 2013
2023
Q3 		– Sell
-2,487
Closed -$100K – 2178
2023
Q2 		$100K Buy
+2,487
New +$141K ﹤0.01% 2323
2022
Q4 		– Sell
-3,064
Closed -$290K – 2921
2022
Q3 		$290K Buy
+3,064
New +$344K ﹤0.01% 2963
2021
Q2 		– Sell
-3,051
Closed -$1.1M – 2635
2021
Q1 		$1.1M Sell
3,051
-22,259
-88% -$9.84M 0.01% 1614
2020
Q4 		$12.4M Buy
25,310
+14,323
+130% +$6.61M 0.07% 289
2020
Q3 		$3.56M Sell
10,987
-19,892
-64% -$6.77M 0.02% 628
2020
Q2 		$11.2M Buy
+30,879
New +$7.8M 0.08% 260
2019
Q2 		– Sell
-286
Closed -$284K – 1342
2019
Q1 		$284K Buy
+286
New +$266K ﹤0.01% 1270

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace's ATRA Position: Q1 2026 in Review

Marshall Wace sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 148,632 shares — an estimated $2.69M sold.

Marshall Wace first reported a position in ATRA in Q1 2019 and held it in 13 quarters. The position peaked at $12.4M in Q4 2020. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Marshall Wace reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 148,632 Atara Biotherapeutics shares in Q1 2026, an estimated $2.69M.
  • Marshall Wace first reported a position in Atara Biotherapeutics in Q1 2019 and held it in 13 quarters.
  • Marshall Wace's Atara Biotherapeutics position peaked at $12.4M in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.